Hudson Bay Capital Management
PVLA

Hudson Bay Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Hudson Bay Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$267K Buy
+2,140
New +$223K ﹤0.01% 1057

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hudson Bay Capital Management's PVLA Position: Q1 2026 in Review

Hudson Bay Capital Management opened a new position in Palvella Therapeutics (PVLA) in Q1 2026: 2,140 shares worth $267K. The stake represents ﹤0.01% of the portfolio and ranks #1057 among its holdings.

180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Hudson Bay Capital Management held 2,140 shares of Palvella Therapeutics worth $267K as of Q1 2026.
  • Palvella Therapeutics was a new Hudson Bay Capital Management position in Q1 2026.
  • Palvella Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #1057 holding.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.